The severe phenotype of leukocyte adhesion deficiency is a rare, congenital disorder of leukocyte function that is usually fatal in the first few years of life. Allogeneic hematopoietic stem cell transplantation currently offers the only curative approach for this disease. We describe the first successful matched unrelated donor bone marrow transplant in an infant with leukocyte adhesion deficiency. Keywords: leukocyte adhesion; marrow transplant; unrelated Leukocyte adhesion deficiency type I (LAD-I) is a rare inherited immunodeficiency caused by a mutation in the gene encoding the beta-2 integrin, CD18. This adhesive protein, defined by a specific monoclonal antibody anti-CD18, is expressed by leukocytes, and is shared by three adhesive heterodimers, LFA-1, Mac-1 (CR3) and p150, 95.
Case report
The patient was the first child of a non-consanguinous Mexican-American couple born at full term by spontaneous vaginal delivery. She was hospitalized at 1 week of age for omphalitis and severe diaper dermatitis which resolved during a 2 week treatment course with intravenous antibiotics. She was readmitted at 24 days of age with fever and irritability; her white blood cell count on admission was 62 600 with a left shift; despite broadspectrum antibiotic therapy, her condition deteriorated; she developed increasing abdominal distention with persistent fever and a rise in her WBC to 78 000/mm 3 . Pseudomonas aeruginosa and Enterococcus spp. were isolated from a perianal lesion. She was treated with intravenous antibiotics for her presumed peritonitis and perianal abscess but developed cellulitis at an intravenous catheter site in her left foot. P. aeruginosa was isolated from the fluid around her cellulitis. She went on to develop P. aeruginosa line sepsis and osteomyelitis of the left metatarsal bones. An immunologic evaluation revealed normal immunoglobulin G, A, M and E levels, normal C3, C4 and CH50, normal proportions of T and B cells and lymphocyte subsets. On flow cytometric evaluation, less than 1% of her peripheral blood white cells expressed CD18. Her lymphocyte proliferative responses to mitogens were normal but the response to allogeneic cells was 5% of that of control lymphocytes. She received several weeks of intravenous antibiotic therapy while awaiting the identification of a suitable donor. In order to ensure eradication of residual infection, she underwent a below knee amputation of her left leg prior to her transplant.
At the age of 4 months, she underwent a matched unrelated donor bone marrow transplant following a conditioning regimen of busulfan 30 mg/m 2 p.o. every 6 h ϫ 16 doses, etoposide 900 mg/m 2 i.v. and cyclophosphamide 50 mg/kg once daily i.v. for 4 days. 4 The donor and recipient were serologically matched at all four HLA-A and B loci and molecularly matched at the DR␤1, DP and DQ loci. The patient received 6.2 ϫ 10 8 nucleated marrow cells per kg of non T cell-depleted marrow. There was prompt hematopoietic engraftment with an absolute neutrophil count of 500/mm 3 by day ϩ16. The patient received a triple-drug graft-versus-host disease (GVHD) prophylaxis regimen of four doses of methotrexate, cyclosporine, and methylprednisolone from day ϩ7 to day ϩ28. 6 The post-transplant course was complicated by moderate oral mucositis, perianal skin breakdown and mild hyperbilirubinemia. Flow cytometric analysis of peripheral blood on day ϩ18 demonstrated CD18 expression on 96% of leukocytes. She was discharged on day ϩ30. She developed no signs of acute skin or gastrointestinal GVHD.
She was readmitted on day ϩ49 for a small bowel obstruction due to an incarcerated umbilical hernia. She underwent an exploratory laparotomy with reduction of an incarcerated distal ileum. She recovered from her surgery uneventfully with rapid wound healing and was discharged 4 days later. Her subsequent post-transplant course was significant for two hospitalizations for bacterial central line infection which resolved with appropriate antimicrobial therapy.
Six months post transplant, she developed hyperpigmented skin lesions over the periorbital areas, posterior trunk and extremities, including redness and peeling of the right sole and both palms with thickening of the skin. Skin biopsy showed some hyperkeratosis with a lymphocytic infiltrate of the basal half of her epidermis, scattered apoptotic keratinocytes and spongiosis with lymphocytic infiltration around dermal capillaries and within hair shafts. The skin lesions responded to treatment with 2 mg/kg of prednisone but she went on to develop chronic extensive skin GVHD. Her chronic GVHD is well controlled with alternate day prednisone at 1 mg/kg prednisone and alternate day oral cyclosporine. 7 She has had no significant infectious complications in association with her chronic GVHD. She is currently 27 months post transplant with some sequelae of chronic GVHD including early joint contractures and patchy hyperpigmentation of skin over her extremities. Flow cytometry continues to demonstrate CD 18 expression on Ͼ95% of her leukocytes (Figure 1 ). Full donor cell chimerism was demonstrated by DNA RFLP analysis. She ambulates well with a prosthesis and has a Lansky score of 90.
Discussion
Allogeneic hematopoietic stem cell transplantation is the only curative therapy available for patients with LAD-I. The high risk of fatal infectious complications during transplantation justifies aggressive therapy to control residual infections prior to HSCT, in this case amputation for chronic osteomyelitis. The bone marrow in patients with LAD, as in other inherited disorders of the myeloidmacrophage lineage, is hyperactive. 8 This necessitates the use of an aggressive myeloablative conditioning regimen in order to overcome graft rejection and facilitate engraftment. 3, 6 Despite the addition of VP-16 to the conditioning regimen, Thomas et al 4 noted mixed but stable chimerism in a number of their survivors. Although second transplants were necessary in five of nine haploidentical parental donor transplants, all nine recipients successfully engrafted suggesting that the absence of LFA-1 on recipient cells, with resultant defective non-T and T cytotoxic activity, may have facilitated engraftment in the haploidentical setting. 3, 4 The development of extensive chronic GVHD in our patient, although not surprising in the context of an unrelated donor transplant, is intriguing in that Thomas and colleagues 4 also noted a trend towards a high rate of both acute and chronic GVHD in their LAD patients, even in those receiving HLA-identical sibling donor BMT. The reasons for this are unknown but it is postulated that the facilitation of engraftment by defective expression of LFA-1 on host lymphocytes indirectly switches the balance in favor of donor lymphocyte reactivity. 4 This is the first report of a successful unrelated donor HSCT in a patient with leukocyte adhesion deficiency. The reported trend towards a higher rate of GVHD in these patients argues in favor of using T cell-depleted donor marrow. However, this may necessitate the use of even more intensive preparative regimens to overcome graft failure. The clinical correction of the disease with just 7% to 30% donor cell chimerism makes gene therapy an attractive therapeutic modality. 3 However, until a normal beta-subunit encoding gene can be successfully introduced into patients' hematopoietic cells by gene transfer, 9 allogeneic HSCT remains the only effective cure for LAD, regardless of whether a related or unrelated donor is used.
